Clinical trials: Respiratory Syncytial Viruses
Lower Respiratory Tract Infection
Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
- Trial name
- CHIMES (NCT05110261)
- Testing
- Nirsevimab
- Where
- 30 sites in China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
RSV Infection
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- Trial name
- NCT04871724
- Testing
- EDP-938, Fluconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years.
- Trial name
- NCT06067230
- Testing
- mRNA-1345
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 1,153 people
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Infections
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
- Trial name
- NCT05879107
- Testing
- RSVPreF3 OA investigational vaccine, PCV20
- Where
- 38 sites in United States, Belgium and 2 more
- Volunteers
- 1,113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
- Trial name
- NCT07764237
- Testing
- mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3)
- Where
- 10 sites in Canada, United Kingdom
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Infectious Disease, Influenza
Antibiotic Therapy in Viral Airway Infections
Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020.
- Conditions
- Infectious Disease, Influenza, Respiratory Syncytial Virus (RSV), Respiratory Tract Infections
- Trial name
- ATHENIAN (NCT05045612)
- Testing
- Stop antibiotic therapy
- Where
- 12 sites in Norway
- Volunteers
- 380 people
- Sponsor
- University Hospital, Akershus
Bronchiolitis, Respiratory Syncytial Virus (RSV)
Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis
In July 2023, the Food and Drug Administration approved nirsevimab (Beyfortus®), a long-acting monoclonal antibody, for passive immunization to prevent RSV-associated lower respiratory tract infection (Bronchiolitis) among…
- Conditions
- Bronchiolitis, Respiratory Syncytial Virus (RSV), Immunization; Infection
- Trial name
- EPINIR-BRONC (NCT06185647)
- Testing
- No intervention. Observational retrospective study
- Where
- France
- Volunteers
- 4,924 people
- Sponsor
- Hôpital Armand Trousseau
Acute Bronchiolitis
FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma
The purpose of this study is to determine Fractional exhaled Nitric-Oxide (FeNO)levels and blood cytokines during acute bronchiolitis, and to seek for correlation between these markers and future development of asthma.
- Trial name
- NCT02093715
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Vaccine Response Impaired, Respiratory Syncytial Virus Infections
RSV Vaccine in Transplant Recipients
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied.
- Conditions
- Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
- Trial name
- RSVax (NCT06593210)
- Testing
- Adjuvant, non-live RSV vaccine
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Respiratory Syncytial Virus Infection, Bronchiolitis
Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young children, and a substantial proportion of severe cases occur in previously healthy infants.
- Conditions
- Respiratory Syncytial Virus Infection, Bronchiolitis, Viral Lower Respiratory Tract Infection (LRTI)
- Trial name
- GUT-LUNG RSV (NCT07417657)
- Where
- Vietnam
- Volunteers
- 250 people
- Sponsor
- Phuc Huu Phan
Respiratory Syncytial Virus Infection
Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Published data by the Organización panamericana de la Salud shows that Peru's mortality rate from acute respiratory infections (ARI) in infants less than one year of life is second only to Haiti (14,150/100,000).
- Trial name
- INSPIRA (NCT01107535)
- Testing
- Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.
- Where
- 4 sites in Peru
- Volunteers
- 82 people
- Sponsor
- Abbott
RESPIRATORY SYNCYTIAL VIRUS (RSV)
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups.
- Trial name
- MONET (NCT05842967)
- Testing
- RSVpreF
- Where
- 36 sites in United States
- Volunteers
- 885 people
- Sponsor
- Pfizer
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Viral Inhibition in Children for Treatment of RSV
VICTOR is a randomized, double-blind, placebo-controlled, multicenter, 2-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants…
- Trial name
- VICTOR (NCT02654171)
- Testing
- AK0529
- Where
- 28 sites in Australia, Hong Kong and 6 more
- Volunteers
- 72 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Syncytial Virus (RSV)
Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
- Trial name
- RSVVaccine (NCT07492706)
- Testing
- MKK900 60 µg, MKK900 120 µg, ABRYSVO®
- Where
- 2 sites in Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
RSV Infection, Disease Burden
Diagnosis and Treatment Status and Medical Burden of Respiratory Syncytial Virus Infection in Children in China
To understand the diagnosis and treatment status and medical burden of respiratory syncytial virus (RSV) infection in children in China, and to provide scientific basis for formulating prevention and treatment strategies for…
- Trial name
- NCT07264478
- Testing
- uninvolved
- Where
- China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Children's Hospital
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants…
- Trial name
- NCT01893554
- Testing
- RSV ΔNS2 Δ1313 I1314L Vaccine
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
RSV Infection, Stem Cell Transplant Complications
Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV
RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study.
- Conditions
- RSV Infection, Stem Cell Transplant Complications, Lower Resp Tract Infection
- Trial name
- REVIRAL2 (NCT04267822)
- Testing
- RV521 oral tablet
- Sponsor
- Pfizer
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients
Respiratory Syncytial Virus - RSV Protocol
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant.
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia
- Trial name
- NCT01502072
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
RSV Infection
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy.
- Trial name
- NCT07824167
- Testing
- Clesrovimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University